InvestorsHub Logo
Post# of 253167
Next 10
Followers 840
Posts 120474
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 203079

Monday, 10/24/2016 9:16:22 AM

Monday, October 24, 2016 9:16:22 AM

Post# of 253167
INO -19%/PM on delayed to VGX-3100 phase-3 program:

http://finance.yahoo.com/news/inovio-announces-fda-request-additional-120000050.html

Inovio Pharmaceuticals, Inc. (INO) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100... This study has not yet been initiated and has not enrolled or dosed subjects. Additionally, the hold does not pertain to any of Inovio’s other ongoing clinical studies.

Inovio anticipates receiving a formal letter with complete information from the FDA within 30 days. In its initial communication, the FDA has requested additional data to support the shelf-life of the newly designed and manufactured disposable parts of the CELLECTRA 5PSP immunotherapy delivery device… Inovio estimates that the start of the phase III clinical program will be delayed until the first half of 2017 pending resolution of the FDA’s requests.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.